Our experiments revealed that two PRMT1-specific inhibitors (AMI-1 and MS023) could decrease HBP1 methylation and increase HBP1 protein levels, thereby enhancing HBP1-mediated suppression of tumor growth and metastasis. Here, HBP1 is linked to neoplasm.